ELDN (Eledon Pharmaceuticals) Change In Receivables: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELDN Eledon Pharmaceuticals Inc ELDN
27 GF Score
Price $3.41
! 1 Warning Sign
View Full Analysis

What is Eledon Pharmaceuticals Change In Receivables?

Eledon Pharmaceuticals ELDN +3.18% 27 Change In Receivables is $0.00 Mil as of Mar. 2026. GuruFocus rates ELDN with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

Eledon Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2026 was $0.00 Mil. It means Eledon Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

Eledon Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Eledon Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Eledon Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Eledon Pharmaceuticals's liquidation value for the three months ended in Mar. 2026 was $9.19 Mil.

Eledon Pharmaceuticals  (NAS:ELDN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Eledon Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Eledon Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Eledon Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=111.089-101.903+0.75 * 0+0.5 * 0
=9.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eledon Pharmaceuticals Change In Receivables Related Terms

Eledon Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for Eledon Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eledon Pharmaceuticals Change In Receivables Chart

Eledon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Eledon Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ELDN
27GF Score
Eledon Pharmaceuticals Inc ELDN
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eledon Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.00 Mil mean?
Eledon Pharmaceuticals (ELDN) has a Change In Receivables of $0.00 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Eledon Pharmaceuticals and its competitors.
Is Eledon Pharmaceuticals' Change In Receivables too high?
Eledon Pharmaceuticals' current Change In Receivables is $0.00 Mil. Overall, Eledon Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Eledon Pharmaceuticals' Change In Receivables compare to NMRA and ALXO?
Eledon Pharmaceuticals' Change In Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Eledon Pharmaceuticals and its competitors. Eledon Pharmaceuticals's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eledon Pharmaceuticals stock overvalued right now?
Eledon Pharmaceuticals (ELDN) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. Eledon Pharmaceuticals' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Eledon Pharmaceuticals (ELDN), the current Change In Receivables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eledon Pharmaceuticals Business Description

Other Exchanges 2TK:Germany
Address 19800 MacArthur Boulevard, Suite 250, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
27GF Score

Get the complete analysis for ELDN

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.41
Price